Get the Stockscreener App
518.39
0.12%
0.64
After Hours:
518.39
Idexx Laboratories Inc stock is traded at $518.39, with a volume of 287.83K.
It is up +0.12% in the last 24 hours and down -3.82% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$517.75
Open:
$523.5
24h Volume:
287.83K
Relative Volume:
0.51
Market Cap:
$40.84B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
38.14
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
-0.17%
1M Performance:
-3.82%
6M Performance:
-8.98%
1Y Performance:
-18.21%
1-Day Range:
$516.02
$524.02
1-Week Range:
$515.12
$536.84
52-Week Range:
$500.61
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
518.39 | 40.91B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
IDEXX Laboratories to Release 2026 Third Quarter Financial Results - 01net
IDEXX Laboratories expands parasite testing ahead of IDEXX Laboratories stock results - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo! Finance Canada
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI - marketscreener.com
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories - PR Newswire
What Does Today’s Signal Mean for IDEXX Laboratories (NASDAQ:IDXX)? - Kalkine Media
IDEXX Laboratories stock after-hours at EUR 471.50: plus 1.34 percent - AD HOC NEWS
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - GlobeNewswire Inc.
IDEXX Laboratories stock gained 1.14 percent on September 25 - AD HOC NEWS
IDEXX Laboratories stock falls 1.65 percent below USD 747 target - AD HOC NEWS
IDEXX Laboratories stock heads into the open after September 24 update - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history - Yahoo Finance Singapore
Should You Continue to Hold IDXX Stock in Your Portfolio? - TradingView
IDEXX Laboratories stock gains as revenue outlook meets premium valuation - AD HOC NEWS
IDEXX Laboratories stock heads into the open after a 1.16 percent gain - AD HOC NEWS
IDEXX Laboratories Acquires CoVetAI to Enhance Veterinary Software Ecosystem - Global Legal Chronicle
IDEXX Laboratories stock gains 1.16 percent as valuation holds - ad-hoc-news.de
IDEXX Laboratories stock heads into the open after recent gains - AD HOC NEWS
IDEXX Laboratories stock gains after double digit Q2 growth and raised guidance - AD HOC NEWS
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof - DVM 360
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets - Yahoo Finance
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference - Yahoo Finance
IDEXX Laboratories stock gains attention after CoVetAI deal and Stifel Buy rating - AD HOC NEWS
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics - Yahoo Finance
IDEXX Laboratories Inc | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
IDEXX Laboratories stock holds after Stifel keeps Buy rating - AD HOC NEWS
Why Is the Market Reassessing IDEXX Laboratories (IDXX)? - Kalkine Media
IDEXX Laboratories stock holds Stifel Buy rating after Q2 earnings beat - ad-hoc-news.de
Stifel reiterates Buy on IDEXX Laboratories stock citing vet survey By Investing.com - Investing.com Australia
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide - Yahoo Finance
IDEXX Laboratories stock heads into the open after a modest pullback - AD HOC NEWS
IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus - Yahoo Finance
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Vet Candy
IDEXX Laboratories stock gains as CoVetAI deal and new parasite tests bolster growth narrative - AD HOC NEWS
IDEXX Stock Gains Following the Acquisition of CoVet - Yahoo Finance
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection - PA Media
UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $670 - Moomoo
IDEXX Laboratories (IDXX) Looks 19.8% Undervalued on GF Value™ - GuruFocus
IDEXX Laboratories Acquires Veterinary AI Software Firm CoVetAI - marketscreener.com
Press Release: IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence - Moomoo
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 38% Potential Upside For Investors - DirectorsTalk Interviews
IDXX - Finviz
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Idexx Laboratories Inc Stock (IDXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kingsley Lawrence D | Director |
Sep 04 '26 |
Sale |
532.08 |
2,203 |
1,172,178 |
9,568 |
2.75%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):